Upgrade to SI Premium - Free Trial

Allergan (AGN) Says Pivotal Trials for OCUN-009 and OCUN-010 Met Primary, Secondary Endpoints

May 16, 2016 7:16 AM
Allergan plc (NYSE: AGN) announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments

Next Articles